ArticleIndian journal of pediatrics2025
Diagnostic Accuracy of Furosemide Stress Test and Cystatin-C for Predicting Acute Kidney Injury Progression in Children: A Prospective Cohort Study.
Article in Indian journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic accuracy of serum cystatin C for pediatric acute kidney injury: a systematic review and meta-analysis.Pediatric nephrology (Berlin, Germany) · 2026Pooled it
- From mechanisms to clinical practice: a review of diuretic therapy in pediatric nephrology.Pediatric nephrology (Berlin, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the predictive ability of furosemide stress test (FST), serum and urine cystatin-C in identifying progressive acute kidney injury (AKI) and the need for kidney replacement therapy (KRT).
methodsChildren aged one month to 18 y admitted in the pediatric intensive care unit (PICU) with Kidney Diseases Improving Global Outcomes (KDIGO) stage-1/2 AKI were enrolled. FST and serum and urine cystatin-C levels were performed and analyzed. The primary outcome was progression to stage-3 AKI. Secondary outcomes included comparing predictive ability of FST vs. cystatin-C for stage-3 AKI and need for KRT, adverse effects, length of hospital stay and mortality.
resultsOf the 41 children enrolled, seven (17.07%) progressed to KDIGO stage-3 AKI. Four children were furosemide non-responders at 2 h and five at 6 h post-FST. The sensitivity, specificity and area under the receiver operating characteristic curve (AUROC) of FST at 2 h were 57.14%, 100% and 0.84 (p = 0.01), and at 6 h were 71.43%, 100% and 0.87 (p < 0.001), respectively. Urine cystatin-C was positive in 20 (48.78%) children, of which seven progressed to stage-3 AKI [sensitivity- 100%, specificity- 61.76%, AUROC- 0.91 (p = 0.003)]. Five of nine children with positive serum cystatin-C progressed to stage-3 AKI [sensitivity- 71.43%, specificity- 88.24%, AUROC- 0.75 (p = 0.08)]. All FST non-responders progressed to undergo KRT showing sensitivity and specificity of 66.67% and 100% at 2 h (AUROC- 0.87) and 85% and 100% at 6 h (AUROC- 0.89) respectively.
conclusionsFST is a simple bedside tool with robust predictive value in detecting kidney impairment progression in children and can be utilized in PICU for assessing tubular dysfunction. The diagnostic accuracy of FST was comparable to that of urine and serum cystatin-C. Further studies can be done on a larger cohort for better generalizability.
Indexed as
Identifiers
39826043What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.